AP
Publicaties op Oncologisch.com
Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Gevorderd-Stage Classic Hodg...
Subsequent Neoplasm Risico After Modern Mediastinal Radiotherapie for Pediatric Hodgkin Lymphoma: Insights From a Multi-Institutional Children’s Oncology Group Trial
Group-based trajectories of health-related quality of life among pediatric patiënten met high-risk Hodgkin lymphoma.
Nivolumab plus AVD bij gevorderd klassiek hodgkinlymfoom: SWOG S1826 fase III
QoL bij hoogrisico pediatrisch hodgkinlymfoom: longitudinale analyse
BV plus chemotherapie bij pediatrisch hoogrisico hodgkinlymfoom: AHOD1331 fase III